Yale University’s Novavax NVAX Stock Holding History

Yale University’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q1	–	Sell	-1,270	Closed	-$130K	–	8
2013 Q4	$130K	Buy	+1,270	New	+$89.7K	0.23%	9

Other funds holding NVAX

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Yale University's NVAX Position: Q1 2014 in Review

Yale University sold out of Novavax (NVAX) in Q1 2014, closing a stake of 1,270 shares — an estimated $130K sold.

Yale University first reported a position in NVAX in Q4 2013 and held it in 1 quarter. The position peaked at $130K in Q4 2013. 141 funds tracked by Wall St. Rank hold NVAX as of Q1 2014.

Yale University reported no remaining Novavax position as of Q1 2014 after selling out during the quarter.
Yale University sold 1,270 Novavax shares in Q1 2014, an estimated $130K.
Yale University first reported a position in Novavax in Q4 2013 and held it in 1 quarter.
Yale University's Novavax position peaked at $130K in Q4 2013.
141 funds tracked by Wall St. Rank held Novavax as of Q1 2014.

Based on Yale University's 13F filing for Q1 2014, filed 14 May 2014.